C4 Therapeutics Inc (CCCC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, C4 Therapeutics Inc (CCCC) has a cash flow conversion efficiency ratio of -0.086x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-22.14 Million) by net assets ($256.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Check C4 Therapeutics Inc strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
C4 Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how C4 Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. See C4 Therapeutics Inc (CCCC) shareholders funds for net asset value and shareholders' equity analysis.
C4 Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of C4 Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ouro Fino Saúde Animal Participações S.A
SA:OFSA3
|
0.125x |
|
Palisade Bio Inc
NASDAQ:PALI
|
-0.024x |
|
Northeast Community Bancorp Inc
NASDAQ:NECB
|
0.040x |
|
RMR Group Inc
NASDAQ:RMR
|
0.121x |
|
Xinjiang Tianshan Animal Husbandry Bio-engineering Co Ltd
SHE:300313
|
-0.931x |
|
Venus Pipes & Tubes Limited
NSE:VENUSPIPES
|
0.057x |
|
Jiangsu Jingxue Insulation
SHE:301010
|
0.044x |
|
Bohai Water Industry Co Ltd
SHE:000605
|
0.008x |
Annual Cash Flow Conversion Efficiency for C4 Therapeutics Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of C4 Therapeutics Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see C4 Therapeutics Inc (CCCC) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $256.59 Million | $-98.69 Million | -0.385x | -27.50% |
| 2024-12-31 | $215.99 Million | $-65.16 Million | -0.302x | +30.51% |
| 2023-12-31 | $246.11 Million | $-106.84 Million | -0.434x | -18.52% |
| 2022-12-31 | $289.23 Million | $-105.94 Million | -0.366x | -64.09% |
| 2021-12-31 | $389.61 Million | $-86.97 Million | -0.223x | +6.80% |
| 2020-12-31 | $280.79 Million | $-67.25 Million | -0.239x | +51.78% |
| 2019-12-31 | $-111.96 Million | $55.61 Million | -0.497x | -333.28% |
| 2018-12-31 | $-79.75 Million | $-16.98 Million | 0.213x | -- |
About C4 Therapeutics Inc
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology p… Read more